If this one holds true ...
... it's an outstanding development for Hep C patients:
Roche announced that new investigational drug for hepatitis C, R1626, has shown promising antiviral efficacy when given in combination with PEGASYS and COPEGUS. After 4 weeks of treatment with the triple combination, the hepatitis C virus could no longer be detected in up to 81% of the hepatitis C-infected patients. The new data were presented at the American Association for the Study of the Liver (AASLD) meeting held in Boston, November 2-6.
Grace and peace ...
Roche announced that new investigational drug for hepatitis C, R1626, has shown promising antiviral efficacy when given in combination with PEGASYS and COPEGUS. After 4 weeks of treatment with the triple combination, the hepatitis C virus could no longer be detected in up to 81% of the hepatitis C-infected patients. The new data were presented at the American Association for the Study of the Liver (AASLD) meeting held in Boston, November 2-6.
Grace and peace ...
Labels: Hep C
posted by Pastor Buzz at 10:03 AM
0 Comments:
Post a Comment
<< Home